Trials / Unknown
UnknownNCT03087695
Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma
Effect of the Plasma EBV DNA Concentration Change During Chemoradiotherapy on Tumor Control and Patient Survival in Advanced Nasopharyngeal Carcinoma
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Taichung Veterans General Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- —
Summary
Epstein-Barr virus (EBV) has been proven to process a strong association in patient of nasopharyngeal carcinoma (NPC). Monitoring plasma EBV DNA in NPC patients can provide reliable informations in early detecting tumor recurrence or risk grouping.
Detailed description
EBV DNA has strongly association in NPC patient' disease status. It can provide informations of disease relapse or risks classification. In this study, we will investigate the impact of plasma EBV DNA concentration change during chemoradiotherapy on initial tumor response and long-term survival in patients with advanced nasopharyngeal carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Plasma EBV DNA | Parameters analyzed will include (1) the change pattern of plasma EBV DNA concentrations, (2) various half-life values (t1/2) of plasma EBV DNA clearance rate calculated over different time periods. |
Timeline
- Start date
- 2017-04-01
- Primary completion
- 2018-01-16
- Completion
- 2019-01-16
- First posted
- 2017-03-22
- Last updated
- 2017-03-22
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT03087695. Inclusion in this directory is not an endorsement.